Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244783 | 0.87 | TRPV1 (0.54) | KMT2ALMNA | |
| SCHEMBL5507744 | 0.86 | LMNA (0.64) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4405908 | 0.82 | RAB9A (0.61) | SMN1; SMN2HPGDTSHR | |
| SCHEMBL5844 | 0.78 | SMN1; SMN2 (0.42) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL21777399 | 0.76 | KMT2A (0.66) | KMT2ALMNASMN1; SMN2HPGDTSHR | |
| SCHEMBL12395310 | 0.76 | LMNA (0.44) | KMT2ALMNASMN1; SMN2LTA4HHPGD | |
| SCHEMBL21774158 | 0.76 | LMNA (0.47) | KMT2ALMNASMN1; SMN2LTA4HHPGD | |
| SCHEMBL23828926 | 0.74 | LTA4H (0.55) | KMT2ALMNASMN1; SMN2LTA4HHPGD | |
| SCHEMBL4411938 | 0.72 | RAB9A (0.57) | KMT2ATSHR | |
| SCHEMBL12394470 | 0.72 | ALDH1A1 (0.63) | KMT2ALMNASMN1; SMN2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191413-A1 | Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | ATLANTA PHARMA AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1812400-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2005090311-A1 | NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191413-A1 | Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | PDE4A, PDE4B, PDE4C | KMT2A 1968/4885LMNA 4187/4885SMN1; SMN2 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.